BCMA-targeting bispecific antibodies represent a major breakthrough in myeloma care, offering a unique and ideal combination of high efficacy, immediate "off-the-shelf" availability, and a favorable patient experience. In his presentation at the IMS 2025 conference, Dr. Andrew J. Yee explained that these transformative therapies, such as teclistamab, elranatamab, and linvoseltamab, can be delivered directly in the community oncology clinic, avoiding the logistical hurdles of cell therapies and marking a new era in treatment accessibility.

A game-changer in efficacy and experience

These three bispecific antibodies have secured approvals for patients with advanced, heavily pre-treated myeloma. The clinical trial results that led to their approval are remarkable for a single-agent, ready-to-use therapy:

Teclistamab: 63% overall response rate (ORR).

Elranatamab: 61% ORR.

Linvoseltamab: Nearly 71% ORR.

These are not just numbers; they represent deep, high-quality responses in patients who had often exhausted all other options. Many achieved minimal residual disease (MRD) negativity, a highly sensitive measure indicating no detectable cancer cells. Beyond the data, Dr. Yee emphasized a crucial point: the patient experience. He shared that after an initial dosing period, patients on these therapies often report feeling exceptionally well—in many cases, the best they have felt in a long time.

A manageable and improving safety profile

The primary side effect of bispecific antibodies is cytokine release syndrome (CRS). However, Dr. Yee reassured that this is a known and manageable issue. To minimize this risk, all these drugs use a "step-up" dosing schedule, where patients receive a few smaller initial doses to gently acclimate their immune system. As a result, most CRS events are low-grade (like a fever) and are almost exclusively limited to this initial period. The risk of severe CRS is very low.

Infections are another key consideration, but the outlook is positive. Dr. Yee noted that with each successive clinical trial, the rate of severe infections has decreased. This improvement is attributed to growing expertise in supportive care, especially the proactive use of intravenous immunoglobulin (IVIG) to help prevent infections before they start.

The future is now: Moving to the front lines

While currently approved for late-stage disease, the future of bispecific antibodies lies in earlier lines of therapy. Numerous trials are already underway evaluating them in less heavily pre-treated patients, with results expected soon. The rationale is simple: if these drugs are this effective in the most advanced cases, they will likely be even more beneficial when a patient's immune system is stronger.

Indeed, trials are already exploring bispecifics in newly diagnosed patients, where they are producing unprecedented depths of response and raising the tantalizing possibility of a cure. This forward momentum carries a clear message for the broader oncology community: now is the time for community oncologists to gain experience with these agents. As approvals expand into earlier settings, having this practical foundation will be essential to bringing these transformative therapies to a much larger group of patients.

BCMA-targeting bispecific antibodies have established themselves as a new pillar of myeloma treatment, offering a remarkable blend of power and practicality. With deep and durable responses in even the most advanced cases, a manageable safety profile that improves with experience, and the convenience of being an "off-the-shelf" product, they are already transforming patient care. As these therapies rapidly move into earlier lines of treatment, their impact is set to grow exponentially, bringing the hope of deeper remissions—and potentially even a cure—closer to reality for more patients than ever before.

HealthTree Foundation's weekly newsletter delivers myeloma news, breaking conference research, FDA approvals, side effect management, patient stories, and more right to your inbox.

Sign Up Today!